Company Overview
Snapshot
Founded in January 2012 by Tuvia Sofinzon and Raphael Nir, ImProDia operates with 1–10 employees. The company has raised $200,000 across two funding rounds, with Citrine S A L participating in one of its funding rounds. In October 2014, ImProDia secured a funding round.
Business overview
ImProDia is a diagnostic company focused on developing novel proprietary biomarkers to monitor the immunity status of patients with chronic inflammatory diseases. Its technology tracks disease regression, recurrence, treatment response, and overall immunity, aiming to identify patients who will benefit most from specific therapeutic treatments and predict complications. The company's R&D efforts are directed towards creating a clinical prototype for multi-center trials, with a focus on product establishment, characterization, process standardization, and quality control validation. ImProDia's technology has potential applications as a prognostic/diagnostic kit for various chronic inflammatory diseases and as a tool for pharmaceutical companies developing new drugs for cancer, Alzheimer's disease, heart disease, rheumatology, and pulmonary diseases. It operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, with a focus on Test Diagnostics & Screening, serving the healthcare and life sciences markets.
Log in to access full profile ›Company Intelligence Q&A
- When was ImProDia founded?
- ImProDia was founded in January 2012.
- Who are the founders of ImProDia?
- ImProDia was founded by Tuvia Sofinzon and Raphael Nir.
- What is ImProDia's primary sector?
- ImProDia's primary sector is Health Tech & Life Sciences.
- How much capital has ImProDia raised?
- ImProDia has raised a total of $200,000.